| PENBRAYA |
125770 |
001 |
351(a) |
Meningococcal Groups A, B, C, W, and Y Vaccine |
Injection |
Intramuscular |
5UG |
Pre-Filled Syringe |
2023/10/20
|
Pfizer Ireland Pharmaceuticals |
Rx |
Licensed |
N/A |
N/A |
| Zymfentra |
761358 |
001 |
351(a) |
infliximab-dyyb |
Injection |
Subcutaneous |
120MG/ML |
Pre-Filled Syringe |
2023/10/20
|
CELLTRION, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Zymfentra |
761358 |
002 |
351(a) |
infliximab-dyyb |
Injection |
Subcutaneous |
120MG/ML |
Autoinjector |
2023/10/20
|
CELLTRION, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Bimzelx |
761151 |
001 |
351(a) |
bimekizumab-bkzx |
Injection |
Subcutaneous |
160MG/ML |
Pre-Filled Syringe |
2023/10/17
|
UCB, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Bimzelx |
761151 |
002 |
351(a) |
bimekizumab-bkzx |
Injection |
Subcutaneous |
160MG/ML |
Autoinjector |
2023/10/17
|
UCB, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Cosentyx |
761349 |
001 |
351(a) |
secukinumab |
Injection |
Intravenous |
125MG/5ML |
Single-Dose Vial |
2023/10/06
|
Novartis Pharmaceuticals Corporation |
Rx |
Licensed |
N/A |
N/A |
| Yuflyma |
761219 |
003 |
351(k) Interchangeable |
adalimumab-aaty |
Injection |
Subcutaneous |
80MG/0.8ML |
Autoinjector |
2023/09/29
|
CELLTRION, Inc. |
Rx |
Licensed |
adalimumab |
Humira |
| Yuflyma |
761219 |
004 |
351(k) Interchangeable |
adalimumab-aaty |
Injection |
Subcutaneous |
80MG/0.8ML |
Pre-Filled Syringe |
2023/09/29
|
CELLTRION, Inc. |
Rx |
Licensed |
adalimumab |
Humira |
| Yuflyma |
761219 |
005 |
351(k) Interchangeable |
adalimumab-aaty |
Injection |
Subcutaneous |
20MG/0.2ML |
Pre-Filled Syringe |
2023/09/29
|
CELLTRION, Inc. |
Rx |
Licensed |
adalimumab |
Humira |
| Tofidence |
761354 |
001 |
351(k) Biosimilar |
tocilizumab-bavi |
Injection |
Intravenous |
80MG/4ML (20MG/ML)
|
Single-Dose Vial |
2023/09/29
|
Biogen MA Inc. |
Rx |
Licensed |
tocilizumab |
Actemra |
| Tofidence |
761354 |
002 |
351(k) Biosimilar |
tocilizumab-bavi |
Injection |
Intravenous |
200MG/10ML (20MG/ML) |
Single-Dose Vial |
2023/09/29
|
Biogen MA Inc. |
Rx |
Licensed |
tocilizumab |
Actemra |
| Tofidence |
761354 |
003 |
351(k) Biosimilar |
tocilizumab-bavi |
Injection |
Intravenous |
400MG/20ML (20MG/ML) |
Single-Dose Vial |
2023/09/29
|
Biogen MA Inc. |
Rx |
Licensed |
tocilizumab |
Actemra |
| Pombiliti |
761204 |
001 |
351(a) |
cipaglucosidase alfa-atga |
Injection |
Intravenous |
105MG |
Single-Dose Vial |
2023/09/28
|
Amicus Therapeutics US, LLC |
Rx |
Licensed |
N/A |
N/A |
| Entyvio |
761133 |
001 |
351(a) |
vedolizumab |
Injection |
Subcutaneous |
108MG/0.68ML |
Pre-Filled Syringe |
2023/09/27
|
Takeda Pharmaceuticals U.S.A., Inc. |
Rx |
Licensed |
N/A |
N/A |
| Entyvio Pen |
761133 |
002 |
351(a) |
vedolizumab |
Injection |
Subcutaneous |
108MG/0.68ML |
Autoinjector |
2023/09/27
|
Takeda Pharmaceuticals U.S.A., Inc. |
Rx |
Licensed |
N/A |
N/A |
| Comirnaty |
125742 |
002 |
351(a) |
COVID-19 Vaccine, mRNA |
For Injection |
Intramuscular |
30UG |
Pre-Filled Syringe |
2023/09/11
|
BioNTech Manufacturing GmbH |
Disc |
Licensed |
N/A |
N/A |
| Comirnaty |
125742 |
003 |
351(a) |
COVID-19 Vaccine, mRNA |
For Injection |
Intramuscular |
30UG |
Single-Dose Vial |
2023/09/11
|
BioNTech Manufacturing GmbH |
Rx |
Licensed |
N/A |
N/A |
| Spikevax |
125752 |
002 |
351(a) |
COVID-19 Vaccine, mRNA |
Injection |
Intramuscular |
50UG/0.5mL |
Pre-Filled Syringe |
2023/09/11
|
ModernaTX, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Spikevax |
125752 |
003 |
351(a) |
COVID-19 Vaccine, mRNA |
Injection |
Intramuscular |
50UG |
Single-Dose Vial |
2023/09/11
|
ModernaTX, Inc. |
Disc |
Licensed |
N/A |
N/A |
| Spikevax |
125752 |
004 |
351(a) |
COVID-19 Vaccine, mRNA |
Injection |
Intramuscular |
50UG |
Multi-Dose Vial |
2023/09/11
|
ModernaTX, Inc. |
Disc |
Licensed |
N/A |
N/A |